Aquestive Therapeutics (AQST) Other Non Operating Income (2019 - 2023)
Aquestive Therapeutics' (AQST) quarterly Other Non Operating Income came in at -$1.0 million in Q4 2023, down 191.5% quarter-over-quarter from -$353000.0 in Q1 2023.
Aquestive Therapeutics (AQST) Other Non Operating Income (2019 - 2023) Analysis & Trends
Aquestive Therapeutics' Other Non Operating Income history runs 3 years deep, the most recent figure standing at -$1.0 million for Q4 2023.
- On a quarterly basis, Other Non Operating Income changed N/A year-over-year to -$1.0 million in Q4 2023; TTM through Sep 2024 was -$1.0 million, a 191.5% decrease from a year earlier, with the FY2023 full-year figure at -$1.4 million, changed N/A from the prior year.
- Other Non Operating Income declined to -$1.0 million in Q4 2023 per AQST's latest filing, from -$353000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $13.8 million in Q4 2021 and bottomed at -$4.9 million in Q3 2019.
- The 3-year median for Other Non Operating Income is -$691000.0 (2023), against an average of $1.9 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Aquestive Therapeutics | 462.24 Mn | 462.24 Mn | 13.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.03 Mn |
| Mar 31, 2023 | -353,000.00 |
| Dec 31, 2021 | 13.82 Mn |
| Sep 30, 2019 | -4.90 Mn |